Microbiology & Pathology in Ohio

Oxyrase, Inc. is a clinical microbiology laboratory supplier specializing in anaerobic culture solutions and oxidation prevention products. Founded in 1987, the company manufactures the patented Oxyrase® Enzyme System, a core technology used in pre-reduced anaerobic sterile (PRAS) media and culture plates designed to create optimal conditions for oxygen-sensitive organisms. The company's product portfolio includes OxyPRAS Plus® plates (Brucella blood agar, PEA, BBE/KVL bi-plates), OxyPlate™ systems, and Oxyrase® for Broth formulations. Beyond anaerobic microbiology, Oxyrase supplies antioxidant solutions and biological preservation products that extend shelf life of sensitive materials and protect microorganisms during cryogenic storage. Products serve hospitals, medical laboratories, research institutions, and quality control facilities. The company also provides OEM and custom formulation services for specialized applications across clinical, pharmaceutical, food quality, and research sectors.

True Indicating LLC is a sterilization and disinfection technology innovator established in 2017, specializing in customized biological and chemical indicators for healthcare, dental, pharmaceutical, industrial, and life science applications. Based in Toledo, Ohio, the company combines over 35 years of combined expertise in microbiology and healthcare technology to develop indicators for traditional sterilization modalities (steam, ethylene oxide, hydrogen peroxide, dry heat, irradiation, formaldehyde, chlorine dioxide) and emerging technologies. True Indicating manufactures biological indicators (BIs), self-contained BIs (SCBIs), inoculated carriers, chemical indicator inks, tapes, integrators, and emulators. The company offers on-site inoculation, propagation of custom organisms, resistance verification testing, sterilization process validation, and consulting services. FDA-registered and ISO 13485:2016 certified, True Indicating provides scaled production with in-house manufacturing infrastructure and serves thousands of healthcare customers requiring quality sterilization assurance and compliance solutions.

DiaPharma Group, Inc. manufactures specialty research and clinical assay kits, reagents, and hemostasis analyzers for bleeding/clotting disorders, thrombosis, liver disease, drug-induced organ injury, and anti-cancer drug development. Founded in 1997, the company employs scientists with expertise in hemostasis, coagulation testing, platelet function analysis, fibrosis biomarkers, and NETosis research. DiaPharma offers chromogenic substrates, ADAMTS13 assays, Factor X testing, and mechanistic biomarkers for MASH, alcoholic liver disease (ALD), and drug-induced liver injury (DILI). The company provides personalized scientific support and customer service to clinical laboratories, research institutions, and pharmaceutical development teams.

MetaMol Theranostics develops a breakthrough diagnostic test for breast cancer risk assessment. The company has identified and validated hOPN-c (osteopontin-C), a protein biomarker that indicates elevated breast cancer risk when detected in breast biopsy samples. Pathologists can apply this test to biopsy specimens to quantify cancer risk, enabling women with breast lumps to make informed treatment decisions. The test delivers risk stratification at a critical clinical decision point, addressing the significant financial and emotional burden of unnecessary breast cancer interventions. MetaMol's diagnostic platform targets pathology laboratories and oncology centers, providing clinical evidence to guide patient management and treatment planning.